Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile

Similar documents
CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk

CHEMOTHERAPY JUNE 1986


日本化学療法学会雑誌第53巻第S-3号


CHEMOTHERAPY



Fig.1 Chemical structure of BAY o 9867

1272 CHEMOTHERAPY MAR. 1975

CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz

CHEMOTHERAPY

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone


CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

Table1MIC of BAY o 9867 against standard strains

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus

CHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str

Fig. 1 Chemical structure of DL-8280


CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle



CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin


Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

CHEMOTHERAPY MAY. 1988

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent

Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study




VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus

VOL.36 S-I CHEMOTHERAPY Tabl 1 List of healthy male volunteers


VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia



CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote


VOL.42 S-1


CHEMOTHERAPY OCT Fig. 1 Chemical structure of CVA-K

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F

VOL. 43 NO. 4

CHEMOTHERAPY

CHEMO THE RAPY OCT. 1994


988 CHEMOTHERAPY NOV. 1971

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega

VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St

THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium

Key words: Surfactant, Tween, Legionella

CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc

Fig. 1 Chemical structure of KW-1070

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin

VOL.27 S-3 CHEMO THERAPY mido)-3-[[[1- (2-dimethylaminoethyl)-1H-tetrazol-5-yl] -thio] methyl]-ceph-3-em-4-carboxylic acid dihydro- S. aureus 209-P JC

CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation

VOL. 34 S-2 CHEMOTH8RAPY 913

Key Words: Klebsiella pneumoniae, CEP-AIS, MIC, "MBC", MIC of drugs in combination

2108 CHEMOTHERAPY SEPT Table 1 Antimicrobial spectrum Fig. 1

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human

Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-

Key words: Disinfectants, Gram negative rods, Bactericidal effect P. aeruginosa 1, P. fluorescens 20 P. putida 179, P. cepacia 216 P. maltophilia 227,

Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection

pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.

Key words:fatty acid,plant oil,staphylococcus aureus,skin care, atopic dermatitis

VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin

日本化学療法学会雑誌第61巻第6号

CHEMOTHERAPY 52 MAY d a a. Normal S. aureus d Đg/ml, 2h; e b b Đg/ml, Abnormal e. division lh; Abnormal thickening division cross f c. 1


THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec LVFX 100 mg 3 / mg 2 / LVFX PK PD mg mg 1 1 AUC/MIC


THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec DNA 2, , % 1.65% 1.17% 90% 9 Escherichia coli -

CHEMOTHERAPY NOV Fig. 1 Imipenem (MK-0787) Enterobacter cloacae Enterobacter aero Morganella morganii Pseudo- Acinet ob acter Staphylococcus aur


CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09330)

THE JAPANESE JOURNAL OF ANTIBIOTICS ( 37 ) methicillin-susceptible Staphylococcus aureus (MSSA) Escherichia coli levof

CHEMOTHERAPY DEC (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecali


Table 1. Antimicrobial drugs using for MIC

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII (45)


VOL. 33 S-5 CHEMO THERAPY Fig. 1 Chemical structure of HAPA-B 1-N-[ (2 S)-3-Amino-2-hydroxypropiony1]-4- O-(6-amino-6 - deoxy-ƒ -D- glucopyranosyl) -6


日本化学療法学会雑誌第64巻第4号


JUNE 1988

VOL. 36 S-3 CHEMOTHERAPY 437

untitled

CHEMOTHERAPY FEB. 1994


180 ( 64 ) THE JAPANESE JOURNAL OF ANTIBIOTICS June 2011 A b group A Streptococcus: GAS GAS 10 meta-analysis 1) 2,3) GAS potential pathogens Tab

56 CHEMOTHERAPY JAN Fig. 1 Effect of Mezlocillin on respiration, blood pressure and ECG in the rabbit

Transcription:

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Key words: temafloxacin, TA-167, Bacteroides fragilis, Clostridium difficile Bacteroides fragilis group Clostridium difficile bivia, Prevotella intermedia, Port'hyromonas gingivalis

CHEMOTHERAPY DEC. 1993 bivia, Fusobacterium vanum C. sordellii Bifidobacterium Lactobacillus B. fragilis group Prevotella Clostridium C. difficle Table 1. Antibacterial spectrum of temafloxacin against gram-negative anaerobic bacteria compared with those of other agents Inoculum size: 106 CFU/ml

Table 2. Antibacterial spectrum of temafloxacin against gram-positive anaerobic bacteria compared with those of other agents Inoculum size: 106 CFU/ml Table 3. Antibacterial spectrum of temafloxacin against gram-positive anaerobic bacteria compared with those of other agents Inoculum size: 106 CFU/ml

CHEMOTHERAPY DEC. 1993 Clostridium Mobituncus spp,, C. vagina., PePtostrePto. Peplostreptococcus anaerobius B. fragilis group coccus magnus, Clostridium perfringens, Mobiluncus spp. B. fragilis Bacteroides ovalus Prevotella intermedia Peptosireptococcus 3. B. fragilis Table 4-1. Antimicrobial activity of temafloxacin and three other quinolones against clinical isolates of gram-negative anaerobic bacteria

VOL.41 5-5 Table 4-2. Antimicrobial activity of temafloxacin and three other quinolones against clinical isolates of gram-positive anaerobic bacteria and Gardnerella vaginalis Temafloxacin (MIC: 12.5 Ag/ml) Ciprofloxacin (MIC: 25 Ag/ml) Fig. 1. Bactericidal activity of temafloxacin and ciprofloxacin against Bacteroides fragilis GAI 5562.

CHEMOTHERAPY DEC. 1993 Table 5. Appearance of Clostridium difficile in murine cecum contents after 5 days of dosing with temafloxacin, ofloxacin, cefixime and cefotaxime All mice (30 }1g) received antimicrobials at a dose of 100 mg/kg once a day for 5 days. Number of mice.

VOL.41 S-5 motherapy 40 (S-2): 30 `36, 1992 8) Kato N, Miyauchi M, Muto Y, Watanabe K and Ueno K: Emergence of fluoroquinolone resistance in Bacteraides fragilis accompanied by resistance to Ĉ-lactam antibiotics. Antimicrob Agent Chemother 32: 1437 `1438, 1988 Activity of temafloxacin, a novel fluoroquinolone, against anaerobic bacteria Naoki Kato, Haru Kato, Yasunori Tanaka, Kaori Tanaka, Kunitomo Watanabe and Kazue Ueno Institute of Anaerobic Bacteriology, Gifu University School of Medicine, 40 Tukasa-machi, Gifu 500, Japan The in vitro activity of temafloxacin(tmfx), a new fluoroquinolone, was evaluated against anaerobic bacteria, and the inducibility of Clostridium difficile overgrowth in murine cecum by 5- day administration of temafloxacin was also studied. The antimicrobial activity of ciprofloxacin, ofloxacin and norfloxacin were compared with that of TMFX. TMFX showed a broad spectrum, and was the most active against 45 reference strains (44 species) tested, although some species of genus Lactobacillus had low susceptibility to this compound. Against all recent clinical isolates tested, TMFX was the most active among antimicrobial agents used; 90% of Bacteroides fragilis isolates were inhibited at 3.13 Đg/ml of the compound. TMFX showed strong bactericidal activity against B. fragilis. A 5-day administration of TMFX did not provoke the overgrowth of C. difficile in murine cecum.

2024 © docsplayer.net プライバシー | 利用規約 | フィードバック